The manifestations of myelofibrosis (MF)
Myelofibrosis (MF) is a heterogeneous clonal myeloid stem cell cancer and belongs to a group of conditions called myeloproliferative neoplasms (MPN).1 MF primarily affects older adults, over the age of 60.1
The manifestations of MF negatively impact patients' quality of life2-6
Incidence: The incidence of myelofibrosis is 0.6 per 100,000 per annum in the UK.7
Clinical presentation hallmarks:8,9
- Anaemia
- Constitutional symptoms
- Splenomegaly
- Thrombocytopenia
Genetics:
Mutations in JAK2, CALR, and MPL are considered driver events.10
- JAK2 V617F mutation, found in 60% of patients11
- CALR mutations, found in 20 - 30% of patients11
- MPL alterations, found in 5 - 10% of patients11
Reduced quality of life (QoL):
MF has been associated with a reduced quality of life, as reported by patients in the MPN Landmark study.12
83% (n=125/151)* to 95% (n=69/73)** of patients with MF reported a reduction in QoL.12,13
Myelofibrosis symptoms and signs:
*Based on a cohort of 699 adult patients with MF, PV, or ET who completed the international MPN Landmark survey, a multi-country, cross-sectional online study.12
**Based on a cohort of 813 adult patients with MF, PV, and ET enrolled in the MPN Landmark survey, a cross-sectional online study, conducted in the United States.13
CALR, calreticulin; ET, essential thrombocythaemia; JAK2, Janus kinase 2; MF, myelofibrosis; MPL, thrombopoietin receptor (myeloproliferative leukaemia protein); MPN, myeloproliferative neoplasm; PV, polycythaemia vera; QoL, quality of life
Incidence of anaemia, thrombocytopenia and transfusions in PMF15
*Based on 1,000 consecutive patients with PMF at time of referral to Mayo Clinic, seen between November 4, 1977, and September 1, 2011. Separate analyses were included for patients seen at time of referral (N=1,000), at initial diagnosis (n=340), within 1 year of diagnosis (n=274) and after more than 1 year of diagnosis (n=386).15
PMF, primary myelofibrosis
Indication
Omjjara ▼ (momelotinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (MF), post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis and who are:
1. Janus Kinase (JAK) inhibitor naïve
or
2. Have been treated with ruxolitinib.16
References
- Harrison C, McLornan D. Myelofibrosis. Hematology. 2014;19(2):120-1.
- Mughal TI et al. Int J Gen Med. 2014;7:89-101.
- Naymagon L et al. HemaSphere. 2017;1(1):e1.
- Mesa R et al. Leuk Res. 2009;33(9):1199-1203.
- Randhawa J et al. J Hematol Oncol. 2012;5:43.
- Scotch A et al. Leuk Res. 2017;63:34-40.
- Incidence Haematology Malignancy Research Network. Accessed September 2026. Available at: https://hmrn.org/statistics/incidence
- Khan MA, Palmer J. Clin Lymphoma Myeloma Leuk. 2025;25(5):293-303.
- Tefferi A. Am J Hematol. 2023;98:801-821.
- Khoury JD et al. Leukemia. 2022;36:1703-1719.
- Mascarenhas J;Leukemia;2023;37;255–264
- Harrison CN et al. Ann Hematol. 2017;96:1653-1665.
- Mesa R et al. BMC Cancer. 2016;16:167.
- Geyer H.L;Blood;2024;123(24);3803-3810.
- Tefferi A et al. Mayo Clin Proc. 2012;87:25-33.
- UK OMJJARA SmPC
▶︎ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to GSK on 0800 221 441, via email: uksafety@gsk.com or at https://gsk.public.reportum.com/
November 2026 | PM-GB-MML-WCNT-260011 (V1.0)